Who are Ivermectin (reference)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Antimoniate of N-methylglucamine, Pyrimethamine (PYR), Ivermectin 1% cream, ''albendazole'' and ''ivermectin'', Ivermectin 1% cream (IVM), Atovaquone Oral Suspension.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ivermectin-reference.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Ivermectin (reference) — Competitive Intelligence Brief

Ivermectin (reference) (Ivermectin (reference)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiparasitic agent. Area: Infectious Disease.

phase 3 Antiparasitic agent Glutamate-gated chloride channels (GluCl) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Ivermectin (reference) (Ivermectin (reference)) — Padagis LLC. Ivermectin binds to glutamate-gated chloride channels in parasitic organisms, causing paralysis and death of the parasite.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ivermectin (reference) TARGET	Ivermectin (reference)	Padagis LLC	phase 3	Antiparasitic agent	Glutamate-gated chloride channels (GluCl)
Antimoniate of N-methylglucamine	Antimoniate of N-methylglucamine	University of Brasilia	marketed	Antiparasitic agent	Leishmania glycolytic enzymes and mitochondrial function
Pyrimethamine (PYR)	Pyrimethamine (PYR)	Erasmus Medical Center	marketed	Antifolate antimalarial and antiparasitic agent	Dihydrofolate reductase (DHFR)
Ivermectin 1% cream	Ivermectin 1% cream	Insel Gruppe AG, University Hospital Bern	marketed	Antiparasitic agent	Glutamate-gated chloride channels
''albendazole'' and ''ivermectin''	''albendazole'' and ''ivermectin''	Centre d'Appui à la lutte contre la Maladie	marketed	Antihelmintic/Antiparasitic agents	β-tubulin (albendazole); glutamate-gated chloride channels (ivermectin)
Ivermectin 1% cream (IVM)	Ivermectin 1% cream (IVM)	Galderma R&D	marketed	Antiparasitic agent	Glutamate-gated chloride channels (invertebrate-specific)
Atovaquone Oral Suspension	Atovaquone Oral Suspension	University of Oxford	marketed	Antiparasitic agent	Cytochrome bc1 complex (Complex III)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiparasitic agent class)

Actavis Inc. · 2 drugs in this class
Galderma R&D · 1 drug in this class
Insel Gruppe AG, University Hospital Bern · 1 drug in this class
Padagis LLC · 1 drug in this class
U.S. Army Medical Research and Development Command · 1 drug in this class
University of Brasilia · 1 drug in this class
University of Oxford · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ivermectin (reference) — Competitive Intelligence Brief. https://druglandscape.com/ci/ivermectin-reference. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab